Catheter Precision, Inc. — fact timeline

Catheter Precision, Inc. reported quarter ended March 31, 2022 results: revenue $9,000.

“revenues of $9,000 were reported in the quarter ended March 31, 2022”

Catheter Precision, Inc. reported quarter ended March 31, 2023 results: revenue $85,000.

“The registrant is able to preliminarily project revenues of approximately $85,000 for the quarter ended March 31, 2023”

David Jenkins was appointed as interim Chief Executive Officer at Catheter Precision, Inc..

“Until a new Chief Executive Officer is identified, David Jenkins, Executive Chairman of the Board, will serve as interim Chief Executive Officer and as the Company’s principal executive officer, effective April 28, 2023.”

Will McGuire resigned as Chief Executive Officer at Catheter Precision, Inc..

“On April 17, 2023, Ra Medical Systems, Inc. (the “Company”) received the resignation of Will McGuire from his positions as Chief Executive Officer and Secretary, and as a member of the Board of Directors, effective April 28, 2023, for personal reasons.”

Brian Conn departed as Acting Chief Financial Officer at Catheter Precision, Inc..

“Ra Medical Systems, Inc. (the “Company”) today announced the appointment of Steven Passey as Chief Financial Officer effective April 1, 2023, replacing Brian Conn, who has been serving as Acting Chief Financial Officer.”

Steven Passey was appointed as Chief Financial Officer at Catheter Precision, Inc..

“Ra Medical Systems, Inc. (the “Company”) today announced the appointment of Steven Passey as Chief Financial Officer effective April 1, 2023, replacing Brian Conn, who has been serving as Acting Chief Financial Officer.”

Catheter Precision, Inc. shareholders approved Approval of adjournment of Special Meeting at the 2023-03-21 meeting.

“5. Proposal No. 5: Approval of the Adjournment of the Special Meeting. The approval of the adjournment of the Special Meeting, if necessary, to continue to solicit votes for Proposal Nos. 1, 2, 3 and 4 was approved based on the following results of voting, although no such adjournment was required as a result of Proposal Nos. 1, 2, 3 and 4 being approved: Votes For Votes Against Abstentions Broker Non-Votes 1,181,196 87,075 36,696 0”

Catheter Precision, Inc. shareholders approved Ratification of independent registered public accounting firm Haskell & White LLP at the 2023-03-21 meeting.

“4. Proposal No. 4: Ratification of Auditors. The appointment of Haskell & White LLP as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2022 was ratified based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 1,248,217 29,547 27,203 0”

Catheter Precision, Inc. shareholders approved Approval of issuance of common stock upon conversion of Series X Preferred Stock at the 2023-03-21 meeting.

“3. Proposal No. 3: Approval, in Accordance with NYSE American Company Guide Section 712(b), the Issuance of Shares of Company Common Stock upon Conversion of Outstanding Series X Preferred Stock. In accordance with NYSE American Company Guide Section 712(b), the issuance of the Common Stock upon conversion of the Company’s Series X Convertible Preferred Stock, par value $0.0001 per share, which shares of Series X Convertible Preferred Stock were issued upon the closing of the merger between the Company and Catheter Precision, Inc., was approved based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 268,043 70,714 6,088 960,122”

Catheter Precision, Inc. shareholders approved Approval of issuance of more than 19.99% of common stock in connection with sale of Class A and B units and upon exercise of Series F and G warrants and conversion of Series A Preferred at the 2023-03-21 meeting.

“2. Proposal No. 2: Approval of, in Accordance with NYSE American Company Guide Section 713(a), the Issuance of More than 19.99% of the Company’s Outstanding Common Stock. In accordance with NYSE American Company Guide Section 713(a), the issuance of more than 19.99% of our outstanding Common Stock (a) in connection with our sale of Class A units, which contain shares of common stock and Series F and G Common Stock Purchase Warrants, and Class B units, which contain shares of Series A Convertible Preferred Stock and Series F and G Common Stock Purchase Warrants, and (b) upon the exercise of the Series F and G Common Stock Purchase Warrants and the conversion of Series A Convertible Preferred Stock, with the right for such potential exercise or conversion to occur immediately, was approved based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 262,554 75,678 6,613 960,122”

Catheter Precision, Inc. shareholders approved Approval of issuance of more than 19.99% of outstanding common stock upon exercise of Series E warrants at the 2023-03-21 meeting.

“1. Proposal No. 1: Approval of, in Accordance with NYSE American Company Guide Section 713(a), the Issuance of More than 19.99% of the Company’s Outstanding Common Stock. In accordance with NYSE American Company Guide Section 713(a), the issuance of more than 19.99% of our outstanding common stock, par value $0.0001 per share upon the exercise of our Series E Common Stock Purchase Warrants, with the right for such potential exercise to occur immediately, was approved based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 259,937 77,670 7,238 960,122”

Catheter Precision, Inc. completed an acquisition involving Catheter Precision, Inc. (closed 2023-01-09).

“On January 9, 2023, Ra Medical Systems, Inc., a Delaware corporation (the “Company” or “Ra Medical”), completed its acquisition (the “Merger”) of Catheter Precision, Inc., a privately-held Delaware corporation (“Catheter”), pursuant to an Amended and Restated Agreement and Plan of Merger, as reported in the Company’s Current Report on Form 8-K filed with the SEC on January 13, 2023.”

Catheter Precision, Inc.: Filed Certificate of Designation for Series X Convertible Preferred Stock establishing rights, preferences, and limitations (effective 2023-01-09).

“On January 9, 2023, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series X Convertible Preferred Stock with the Secretary of State of the State of Delaware (the “Series X Certificate of Designation”)”

Catheter Precision, Inc. completed an acquisition involving Catheter Precision, Inc. (closed 2023-01-09).

“On January 9, 2023, Ra Medical Systems, Inc., a Delaware corporation (the “Company” or “Ra Medical”), completed its acquisition of Catheter Precision, Inc., a privately-held Delaware corporation (“Catheter”), pursuant to an Amended and Restated Agreement and Plan of Merger (the “Merger Agreement”)”

Catheter Precision, Inc. entered into Amended and Restated Agreement and Plan of Merger with Catheter Precision, Inc., Rapid Merger Sub 1, Inc., and Rapid Merger Sub 2, LLC (effective 2023-01-09).

“On January 9, 2023, Ra Medical Systems, Inc., a Delaware corporation (the “Company” or “Ra Medical”), completed its acquisition of Catheter Precision, Inc., a privately-held Delaware corporation (“Catheter”), pursuant to an Amended and Restated Agreement and Plan of Merger (the “Merger Agreement”), by and among the Company, Catheter, Rapid Merger Sub 1, Inc., a newly-created wholly-owned subsidiary of the Company (“First Merger Sub”), and Rapid Merger Sub 2, LLC, a newly-created wholly owned subsidiary of the Company (“Second Merger Sub” and together with First Merger Sub, the “Merger Subs”), entered into on January 9, 2023”

James Caruso was appointed as Director at Catheter Precision, Inc..

“Pursuant to the terms of the Merger Agreement, as of immediately following the First Effective Time, Richard Mejia, Jr. and Joan Stafslien resigned from the Board of Directors and any committees of the Board of Directors to which they belonged and David Jenkins (Class II) and James Caruso (Class III) were appointed to the Board of Directors, with Mr. Jenkins becoming Executive Chairperson of the Board”

David Jenkins was appointed as Executive Chairperson of the Board at Catheter Precision, Inc..

“Pursuant to the terms of the Merger Agreement, as of immediately following the First Effective Time, Richard Mejia, Jr. and Joan Stafslien resigned from the Board of Directors and any committees of the Board of Directors to which they belonged and David Jenkins (Class II) and James Caruso (Class III) were appointed to the Board of Directors, with Mr. Jenkins becoming Executive Chairperson of the Board”

Joan Stafslien resigned as Director at Catheter Precision, Inc..

“Pursuant to the terms of the Merger Agreement, as of immediately following the First Effective Time, Richard Mejia, Jr. and Joan Stafslien resigned from the Board of Directors and any committees of the Board of Directors to which they belonged and David Jenkins (Class II) and James Caruso (Class III) were appointed to the Board of Directors, with Mr. Jenkins becoming Executive Chairperson of the Board”

Richard Mejia, Jr. resigned as Director at Catheter Precision, Inc..

“Pursuant to the terms of the Merger Agreement, as of immediately following the First Effective Time, Richard Mejia, Jr. and Joan Stafslien resigned from the Board of Directors and any committees of the Board of Directors to which they belonged and David Jenkins (Class II) and James Caruso (Class III) were appointed to the Board of Directors, with Mr. Jenkins becoming Executive Chairperson of the Board”

Catheter Precision, Inc. reported financial results for the nine months ended September 30, 2022.

“On November 14, 2022, Ra Medical Systems, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2022.”

Catheter Precision, Inc. reported financial results for the three months ended September 30, 2022.

“On November 14, 2022, Ra Medical Systems, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2022.”

Catheter Precision, Inc. terminated Lease Termination Agreement with Anaya Holdings LLC valued at released right to $36,017.14 security deposit and paid $300,000 termination fee (effective 2022-10-28).

“Effective as of October 28, 2022, Ra Medical Systems, Inc. (the “Company”) entered into a lease termination agreement with Anaya Holdings LLC (the “Landlord”) (the “Lease Termination Agreement”) dated October 24, 2022, pursuant to which it terminated its lease agreement relating to the premises located at 2070 Las Palmas Drive, Carlsbad, CA 92011 (the “Lease Agreement”).”

Brian Conn was appointed as interim Chief Financial Officer at Catheter Precision, Inc..

“On July 14, 2022, the board of directors of the Company appointed Brian Conn to act as interim Chief Financial Officer effective immediately.”

Jonathan Will McGuire was appointed as interim Chief Financial Officer at Catheter Precision, Inc..

“On July 8, 2022, the board of directors of the Company appointed Jonathan Will McGuire to act as interim Chief Financial Officer effective immediately.”

Jonathan Will McGuire was appointed as interim Chief Financial Officer at Catheter Precision, Inc..

“On July 8, 2022, the board of directors of the Company appointed Jonathan Will McGuire to act as interim Chief Financial Officer effective immediately.”

Andrew Jackson departed as Chief Financial Officer and Secretary at Catheter Precision, Inc..

“On May 10, 2022, Andrew Jackson notified Ra Medical Systems, Inc. (the “Company”) that he will resign as the Company’s Chief Financial Officer and Secretary, effective May 25, 2022.”

William R. Enquist, Jr. resigned as Director at Catheter Precision, Inc..

“On December 17, 2021, William R. Enquist, Jr. notified Ra Medical Systems, Inc. (the “Company”) that, effective December 31, 2021, he is resigning from the Company’s Board of Directors (the “Board”) as well as from the Nominating and Corporate Governance Committee and the Compensation Committee.”

Daniel Horwood resigned as General Counsel and Secretary at Catheter Precision, Inc..

“On July 23, 2021, Daniel Horwood notified Ra Medical Systems, Inc. (the “Company”) that he will resign as the Company’s General Counsel and Secretary, effective July 30, 2021.”